CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG

STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories

APL Healthcare’s Unit-IV classified as VAI by the USFDA

This inspection is now closed

Eugia Pharma launches Pomalidomide capsules in US market

Eugia Pharma receives USFDA Approval for Everolimus tablets

Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules

CuraTeQ Biologics and BioFactura USA to terminate agreement mutually

Apitoria Pharma receives 3 observations from USFDA for Unit-V

The company will respond to the US FDA within the stipulated timelines

CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar

Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints

Apitoria Pharma receives 5 observations from USFDA for API facility

At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported

CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA

Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission

Aurobindo to acquire Lannett Company for Rs. 2,185 Cr

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities